Genetic alteration of histone lysine methyltransferases and their significance in renal cell carcinoma

Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/β-catenin signaling

(2018) Chaoying Jiang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

High-Level Expression of RIPK4 and EZH2 Contributes to Lymph Node Metastasis and Predicts Favorable Prognosis in Patients With Cervical Cancer

(2017) Susan Azizmohammadi et al.   ONCOLOGY RESEARCH

Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA

(2017) Katarzyna Kluzek et al.   Oncotarget

WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer

(2017) Vassiliki Saloura et al.   Scientific Reports

Dual Chromatin and Cytoskeletal Remodeling by SETD2

(2016) In Young Park et al.   CELL

Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer

(2016) Ke Chen et al.   CLINICAL CANCER RESEARCH

Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma

(2016) YOSHIKAZU TOGO et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation

(2016) Kathryn E. Hacker et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer

(2016) Jonathan C. Irish et al.   Molecular Oncology

Identification of genes associated with renal cell carcinoma using gene expression profiling analysis

(2016) TING YAO et al.   Oncology Letters

Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma

(2016) Yang Qu et al.   Oncotarget

SETD2: an epigenetic modifier with tumor suppressor functionality

(2016) Jun Li et al.   Oncotarget

Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma

(2016) Jun Li et al.   NEOPLASIA

Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication

(2015) Ana Sílvia Pires-Luís et al.   Epigenetics

BAP1,PBRM1andSETD2in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies

(2015) Francesco Piva et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death

(2015) Thai H Ho et al.   MODERN PATHOLOGY

SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair

(2015) N Kanu et al.   ONCOGENE

Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma

(2015) Francesco Piva et al.   Oncotarget

Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma

(2015) Rochelle L. Tiedemann et al.   Oncotarget

Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma

(2015) Yang-Fan Lv et al.   Scientific Reports

Genetic alterations of histone lysine methyltransferases and their significance in breast cancer

(2015) Lanxin Liu et al.   Oncotarget

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

New insights on chromatin modifiers and histone post-translational modifications in renal cell tumours

(2014) Márcia Vieira-Coimbra et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Whole Transcriptome Sequencing Reveals Extensive Unspliced mRNA in Metastatic Castration-Resistant Prostate Cancer

(2014) Adam G. Sowalsky et al.   MOLECULAR CANCER RESEARCH

Driver mutations of cancer epigenomes

(2014) David M. Roy et al.   Protein & Cell

Interplay between the Cancer Genome and Epigenome

(2013) Hui Shen et al.   CELL

Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention

(2013) Xuejiao Tian et al.   CURRENT CANCER DRUG TARGETS

SET for life: biochemical activities and biological functions of SET domain-containing proteins

(2013) Hans-Martin Herz et al.   TRENDS IN BIOCHEMICAL SCIENCES

Histone methylation: a dynamic mark in health, disease and inheritance

(2012) Eric L. Greer et al.   NATURE REVIEWS GENETICS

Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma

(2011) Michele Avissar-Whiting et al.   Epigenetics

The von Hippel–Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C

(2011) X Niu et al.   ONCOGENE

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma

(2010) Nina Wagener et al.   BMC CANCER

Expression Profile of the Polycomb Group Protein Enhancer of Zeste Homologue 2 and its Prognostic Relevance in Renal Cell Carcinoma

(2009) Stefan Hinz et al.   JOURNAL OF UROLOGY

Histone methyltransferases in cancer

(2009) Mareike Albert et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Theenhancer of zeste homolog 2gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells

(2008) Nina Wagener et al.   INTERNATIONAL JOURNAL OF CANCER